A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
← catalyst calendarNCT06952803 · readout in 2,415 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
700estimated
Sites
342
Countries
Argentina, Australia, Austria +25
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-06 | actual | When the study began enrolling |
| Primary completion | 2033-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2036-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Prostate Cancer
Interventions
- Drug: Saruparib — also filed as AZD5305
- Drug: Placebo
- Drug: Abiraterone + Prednisolone/Prednisone
- Drug: Androgen Deprivation Therapy (ADT)
Primary outcome
what the primary-completion date above is the date OFMetastasis-free survival (MFS)
measured Up to approximately 93 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed